Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34596877

about

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations Third-line systemic treatment for non-small cell lung cancer Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901 Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials.Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02 Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.[Gefitinib for non-small cell lung cancer: a meta analysis].Network meta-analysis of survival data with fractional polynomials.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Management of patients with advanced non-small cell lung cancer: role of gefitinib High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.Gefitinib in non small cell lung cancer Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC The epidermal growth factor receptor (EGRF) in lung cancer.Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future

P2860

Q21132357-65B6793F-48A1-4CB3-BCB5-CA1213108B75 Q24194090-64520586-7B84-4447-AF8A-F6C0F9ECE7AC Q26768125-A68CF88E-110E-413B-AA69-359C7390242E Q26782809-AA04D27F-A27B-42DB-ADE9-59CDF14A3D3D Q26825636-6B485762-B36A-4B34-9593-9FBEF5EE6DD1 Q27022535-79AB1EFD-7AE6-4B62-94F2-E0ED370A041C Q27851583-8CB257EC-2F17-4098-98B9-6F1843B376F2 Q28284519-7EE71328-5C52-468B-94DA-9B68AD6AEEC1 Q30248499-B9B48CF0-BCEE-4579-99C8-BB12D2CEB392 Q30249335-7D67F337-B9BC-47EC-9F25-6938F32AB9ED Q30279226-673554C0-A5E8-4527-80E6-F07FCAF176FA Q30356434-D7D395D4-DFB0-474A-9037-8243FE70457A Q31036511-2730B5F6-7D6C-4BE0-8A0F-FFA683F1A7A7 Q33403640-16E570EE-511F-4DC2-B0BE-D7660253EF21 Q33406103-231AB672-B405-46F0-8729-887DC4BA323B Q33407582-5120FFC6-882E-47B2-B340-01FF3B22546E Q33411038-CCC55CD7-105F-40E5-8919-1A41F9D5B582 Q33416457-91427B07-83DD-4C51-B3C0-478C9AC6B648 Q33441413-4E79FA07-7767-4399-BD3E-30CAC8026376 Q33490820-A506AFBE-2EBC-43AA-9973-EA5BF16B9A0A Q33534853-908A3C5D-B697-4A5C-A73B-446F1798ED1E Q33599398-77B3E5BB-E10E-4FB2-9D3C-D1A8F1F1ADF2 Q33710152-185694A6-999B-4281-8CB9-ABC84CFCC67E Q33781655-4F6F8FBE-8FBB-40FE-8CB0-8371A1B87797 Q33874571-DAF54DDB-3306-444C-9B0A-8D24A4A74122 Q33891529-3A402736-94E8-4045-8DA3-3C63573F6521 Q33892582-0CE77234-5F6E-469C-9EDD-E08D88753C6C Q33892597-0EAA32FB-BE7C-46CE-948F-72F113BEA1E3 Q33968079-D3ADCD5F-2D62-43ED-93BD-7F8D6D78BE29 Q34272887-2699ED62-1299-459C-AFC1-D5CC53DE6A71 Q34339890-1B9E7842-4215-43FD-91A9-E8207D1CFBE2 Q34404209-7D0B536C-B968-436D-9E85-C639CA0BD5A2 Q34452186-3E26EFC0-CC37-47A0-9B07-11F43DA81522 Q34498728-C8633238-9EC6-4A01-955A-0924F7B912F1 Q34685531-32E9BE0A-0621-488A-8782-DE28A56B3DB8 Q34906960-65D841D8-12FA-4CED-B1A9-F4F0A9ADBB39 Q35031807-3BA7F86F-93EA-433D-8227-B2DBC1AB5034 Q35050210-475BF9D2-0462-473C-AC9A-A24E3FFFD25D Q35196749-D897D395-BD95-4AA8-B7E0-D64F156492CF Q35290807-D0CEF0F3-F01A-46DE-BAAB-56B33645B94B

P2860

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34596877

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@ast

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@en

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@nl

type

label

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@ast

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@en

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@nl

prefLabel

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@ast

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@en

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@nl

P1433

Q34596877-95DCDFF0-FCF9-4C82-BB91-D4363E454758

P1476

Q34596877-D98774F1-DFEC-4760-A266-93D0775F08E9

P2093

Q34596877-0A0570DE-CF08-400B-8809-7B3F351848C6

Q34596877-1DD5E7EB-CC7D-40D4-BDF7-7D64A2F04B0E

Q34596877-25BCCAD4-DE1E-4F54-9099-B69E72886924

Q34596877-3F5D8AF9-6983-4FCB-AA27-FAA353994AE5

Q34596877-4A4ADDF5-962A-483D-88FD-BAFD131CD870

Q34596877-590BB17B-D7CC-4A14-AB64-2D45D658D8A6

Q34596877-7100C1F3-0346-406C-9698-6CC23E1E99CA

Q34596877-74861FA3-55A3-48C0-945B-E31BAFE9CB82

Q34596877-7523AA5A-5274-4BE4-8CCD-079B1A95F377

Q34596877-991C868E-A199-44F6-83DE-BBC3A75E07C4

P304

Q34596877-34F8FAE5-4D31-4580-9954-8C8B4B3DFB04

P31

Q34596877-7C7FCEE6-E82D-451D-9F57-744D2CEB90A7

P356

Q34596877-44E1582F-A8D6-409F-8F32-8F0DB0951AD2

P407

Q34596877-E0FEF3AB-45FD-4835-8896-D394724BB458

P433

Q34596877-18151A10-85CF-491B-920F-05789CC030EA

P478

Q34596877-1CF27C0C-6D7B-4A77-A332-BF8457295CDF

P577

Q34596877-DAF0F83E-945C-4B01-B613-667C72B06481

P698

Q34596877-6DC5AC89-FC1C-450B-81E4-F78B321046E1

P356

JCO.2007.15.0185

P1433

Journal of Clinical Oncology

P1476

Phase III study, V-15-32, of g ...... th non-small-cell lung cancer.

@en

P2093

Akira Inoue

http://www.w3.org/2001/XMLSchema#string

Fumio Imamura

http://www.w3.org/2001/XMLSchema#string

Haiyi Jiang

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Nakagawa

http://www.w3.org/2001/XMLSchema#string

Keisuke Tomii

http://www.w3.org/2001/XMLSchema#string

Kenji Eguchi

http://www.w3.org/2001/XMLSchema#string

Koji Takeda

http://www.w3.org/2001/XMLSchema#string

Masahiro Fukuoka

http://www.w3.org/2001/XMLSchema#string

Masahiro Tsuboi

http://www.w3.org/2001/XMLSchema#string

Masao Harada

http://www.w3.org/2001/XMLSchema#string

P304

4244-4252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.0185

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18779611

http://www.w3.org/2001/XMLSchema#string